147 related articles for article (PubMed ID: 34785505)
21. Interleukin-2 gene transfer potentiates the alpha-galactosylceramide-stimulated antitumor effect by the induction of TRAIL in NKT and NK cells in mouse models of subcutaneous and metastatic carcinoma.
Nishihori Y; Kato K; Tanaka M; Okamoto T; Hagiwara S; Araki N; Kogawa K; Kuribayashi K; Nakamura K; Niitsu Y
Cancer Biol Ther; 2009 Sep; 8(18):1763-70. PubMed ID: 19901518
[TBL] [Abstract][Full Text] [Related]
22. Expression of CD1c enhances human invariant NKT cell activation by α-GalCer.
Fox LM; Miksanek J; May NA; Scharf L; Lockridge JL; Veerapen N; Besra GS; Adams EJ; Hudson AW; Gumperz JE
Cancer Immun; 2013; 13():9. PubMed ID: 23885215
[TBL] [Abstract][Full Text] [Related]
23. α-GalCer and iNKT Cell-Based Cancer Immunotherapy: Realizing the Therapeutic Potentials.
Zhang Y; Springfield R; Chen S; Li X; Feng X; Moshirian R; Yang R; Yuan W
Front Immunol; 2019; 10():1126. PubMed ID: 31244823
[TBL] [Abstract][Full Text] [Related]
24. Activation of hepatic iNKT2 cells by α-GalCer ameliorates hepatic steatosis induced by high-fat diet in C57BL/6J mice.
Chen D; Gao X; Wang J; Zhao H; Liu H; Chen S; Zhang J; Meng M
Int Immunopharmacol; 2019 Sep; 74():105727. PubMed ID: 31284229
[TBL] [Abstract][Full Text] [Related]
25. Dissociated expression of natural killer 1.1 and T-cell receptor by invariant natural killer T cells after interleukin-12 receptor and T-cell receptor signalling.
Emoto M; Shimizu T; Koike H; Yoshizawa I; Hurwitz R; Kaufmann SH; Emoto Y
Immunology; 2010 Jan; 129(1):62-74. PubMed ID: 20028429
[TBL] [Abstract][Full Text] [Related]
26. NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells.
Hermans IF; Silk JD; Gileadi U; Salio M; Mathew B; Ritter G; Schmidt R; Harris AL; Old L; Cerundolo V
J Immunol; 2003 Nov; 171(10):5140-7. PubMed ID: 14607913
[TBL] [Abstract][Full Text] [Related]
27. Retinoic acid induction of CD1d expression primes chronic lymphocytic leukemia B cells for killing by CD8
Ghnewa YG; O'Reilly VP; Vandenberghe E; Browne PV; McElligott AM; Doherty DG
Clin Immunol; 2017 Oct; 183():91-98. PubMed ID: 28780376
[TBL] [Abstract][Full Text] [Related]
28. Tailored design of NKT-stimulatory glycolipids for polarization of immune responses.
Hung JT; Huang JR; Yu AL
J Biomed Sci; 2017 Mar; 24(1):22. PubMed ID: 28335781
[TBL] [Abstract][Full Text] [Related]
29. α-Galactosylceramide treatment before allergen sensitization promotes iNKT cell-mediated induction of Treg cells, preventing Th2 cell responses in murine asthma.
Chen Q; Guo X; Deng N; Liu L; Chen S; Wang A; Li R; Huang Y; Ding X; Yu H; Hu S; Nie H
J Biol Chem; 2019 Apr; 294(14):5438-5455. PubMed ID: 30745361
[TBL] [Abstract][Full Text] [Related]
30. β-mannosylceramide activates type I natural killer t cells to induce tumor immunity without inducing long-term functional anergy.
O'Konek JJ; Kato S; Takao S; Izhak L; Xia Z; Illarionov P; Besra GS; Terabe M; Berzofsky JA
Clin Cancer Res; 2013 Aug; 19(16):4404-11. PubMed ID: 23804426
[TBL] [Abstract][Full Text] [Related]
31. α-Galactosylceramide-induced airway eosinophilia is mediated through the activation of NKT cells.
Chuang YH; Wang TC; Jen HY; Yu AL; Chiang BL
J Immunol; 2011 Apr; 186(8):4687-92. PubMed ID: 21383248
[TBL] [Abstract][Full Text] [Related]
32. Synthesis of C-5″ and C-6″-modified α-GalCer analogues as iNKT-cell agonists.
Guillaume J; Pauwels N; Aspeslagh S; Zajonc DM; Elewaut D; Van Calenbergh S
Bioorg Med Chem; 2015 Jul; 23(13):3175-82. PubMed ID: 26003341
[TBL] [Abstract][Full Text] [Related]
33. Novel in vitro invariant natural killer T cell functional assays.
Balasko A; Graydon C; Fowke KR
J Immunol Methods; 2021 Dec; 499():113171. PubMed ID: 34706265
[TBL] [Abstract][Full Text] [Related]
34. Administration of anti-CD25 mAb leads to impaired α-galactosylceramide-mediated induction of IFN-γ production in a murine model.
Rosalia RA; Štěpánek I; Polláková V; Šímová J; Bieblová J; Indrová M; Moravcová S; Přibylová H; Bontkes HJ; Bubeník J; Sparwasser T; Reiniš M
Immunobiology; 2013 Jun; 218(6):851-9. PubMed ID: 23182710
[TBL] [Abstract][Full Text] [Related]
35. Activation of invariant NKT cells confers protection against Chlamydia trachomatis-induced arthritis.
Bharhani MS; Chiu B; Na KS; Inman RD
Int Immunol; 2009 Jul; 21(7):859-70. PubMed ID: 19477915
[TBL] [Abstract][Full Text] [Related]
36. Early activation of invariant natural killer T cells in a rheumatoid arthritis model and application to disease treatment.
Miellot-Gafsou A; Biton J; Bourgeois E; Herbelin A; Boissier MC; Bessis N
Immunology; 2010 Jun; 130(2):296-306. PubMed ID: 20113367
[TBL] [Abstract][Full Text] [Related]
37. Redirecting iNKT Cell Antitumor Immunity with α-GalCer/CD1d-scFv Fusion Proteins.
Zhang L; Donda A
Methods Mol Biol; 2021; 2388():175-180. PubMed ID: 34524672
[TBL] [Abstract][Full Text] [Related]
38. Serial Stimulation of Invariant Natural Killer T Cells with Covalently Stabilized Bispecific T-cell Engagers Generates Antitumor Immunity While Avoiding Anergy.
Kharkwal SS; Johndrow CT; Veerapen N; Kharkwal H; Saavedra-Avila NA; Carreño LJ; Rothberg S; Zhang J; Garforth SJ; Jervis PJ; Zhang L; Donda A; Besra AK; Cox LR; Almo SC; Howell A; Evans EE; Zauderer M; Besra GS; Porcelli SA
Cancer Res; 2021 Apr; 81(7):1788-1801. PubMed ID: 33483371
[TBL] [Abstract][Full Text] [Related]
39. Dual Modifications of α-Galactosylceramide Synergize to Promote Activation of Human Invariant Natural Killer T Cells and Stimulate Anti-tumor Immunity.
Chennamadhavuni D; Saavedra-Avila NA; Carreño LJ; Guberman-Pfeffer MJ; Arora P; Yongqing T; Pryce R; Koay HF; Godfrey DI; Keshipeddy S; Richardson SK; Sundararaj S; Lo JH; Wen X; Gascón JA; Yuan W; Rossjohn J; Le Nours J; Porcelli SA; Howell AR
Cell Chem Biol; 2018 May; 25(5):571-584.e8. PubMed ID: 29576533
[TBL] [Abstract][Full Text] [Related]
40. Activation of Invariant Natural Killer T Cell Subsets in C57BL/6J Mice by Different Injection Modes of α-galactosylceramide.
Meng M; Chen S; Gao X; Liu H; Zhao H; Zhang J; Zhang J; Chen D
Iran J Allergy Asthma Immunol; 2020 Feb; 19(1):35-44. PubMed ID: 32245319
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
